ReMyelin | The Cell Biology of Remyelination

Summary
The failure of the endogenous regenerative process – remyelination - in chronic Multiple Sclerosis (MS) lesions leaves axons denuded of myelin and contributes to the neurodegeneration that underlies the progressive disability associated with the disease. Stimulating effective remyelination is therefore a key goal for regenerative medicine. Neuropathological studies in humans and animal models have shown that remyelination results in short, thin myelin sheaths. predicted to be less efficient at accelerating conduction and providing axonal metabolic support - two key functions of the myelin sheath. To this end, this project (ReMyelin) examines intrinsic and extrinsic mechanisms that might explain these short, thin sheaths. We propose that they result from a combination of altered intrinsic and extrinsic pathways affecting the myelination process. Intrinsic pathways will be revealed by an innovative three-dimensional culture system using artificial axons developed in the laboratory of the host investigator, enabling changes associating with ageing to be revealed, whilst extrinsic pathways will be revealed using a genetic approach that allows the visualization of newly-generated myelin-forming cells (oligodendrocytes) and their myelin sheaths in demyelinated lesions of mice. These studies on the extrinsic pathway will focus on the role of axonal activity, using chemogenetics to activate or inhibit axonal activity focally and rehabilitation to activate the system more globally. Together these experimental approaches will identify the causes for altered sheath geometry in remyelination, with these new discoveries then underpinning future studies targeting these pathways so as to enhance remyelination.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/835744
Start date: 01-04-2019
End date: 30-09-2021
Total budget - Public funding: 212 933,76 Euro - 212 933,00 Euro
Cordis data

Original description

The failure of the endogenous regenerative process – remyelination - in chronic Multiple Sclerosis (MS) lesions leaves axons denuded of myelin and contributes to the neurodegeneration that underlies the progressive disability associated with the disease. Stimulating effective remyelination is therefore a key goal for regenerative medicine. Neuropathological studies in humans and animal models have shown that remyelination results in short, thin myelin sheaths. predicted to be less efficient at accelerating conduction and providing axonal metabolic support - two key functions of the myelin sheath. To this end, this project (ReMyelin) examines intrinsic and extrinsic mechanisms that might explain these short, thin sheaths. We propose that they result from a combination of altered intrinsic and extrinsic pathways affecting the myelination process. Intrinsic pathways will be revealed by an innovative three-dimensional culture system using artificial axons developed in the laboratory of the host investigator, enabling changes associating with ageing to be revealed, whilst extrinsic pathways will be revealed using a genetic approach that allows the visualization of newly-generated myelin-forming cells (oligodendrocytes) and their myelin sheaths in demyelinated lesions of mice. These studies on the extrinsic pathway will focus on the role of axonal activity, using chemogenetics to activate or inhibit axonal activity focally and rehabilitation to activate the system more globally. Together these experimental approaches will identify the causes for altered sheath geometry in remyelination, with these new discoveries then underpinning future studies targeting these pathways so as to enhance remyelination.

Status

CLOSED

Call topic

MSCA-IF-2018

Update Date

28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.3. EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (MSCA)
H2020-EU.1.3.2. Nurturing excellence by means of cross-border and cross-sector mobility
H2020-MSCA-IF-2018
MSCA-IF-2018